A novel Blood-brain Barrier-permeable peptide, dNP2, conjugated with ctCTLA-4 protein for treating central nervous disorders

An estimated 2.3 million people worldwide have multiple sclerosis or MS, an autoimmune disease with widespread prevalence. MS is caused by autoreactive T cells that cross the blood-brain barrier, or BBB, and induce inflammation and cause damage in the brain and spinal cord. Treatments for MS have been hampered by the difficulty in developing therapeutic molecules that can cross the blood-brain barrier. Researchers at Hanyang University have now identified a novel BBB-permeable peptide that can improve drug delivery to the central nervous system. For more information, please click here.

An estimated 2.3 million people worldwide have multiple sclerosis or MS, an autoimmune disease with widespread prevalence. MS is caused by autoreactive T cells that cross the blood-brain barrier, or BBB, and induce inflammation and cause damage in the brain and spinal cord. Treatments for MS have been hampered by the difficulty in developing therapeutic molecules that can cross the blood-brain barrier. Researchers at Hanyang University have now identified a novel BBB-permeable peptide that can improve drug delivery to the central nervous system. For more information, please click here.